Midkiff K, Andrews EB, Gilsenan A, Harris D. Comparing strategies to monitor for a potential association between teriparatide and adult osteosarcoma. Poster presented at the 10th Asian Conference on Pharmacoepidemiology (ACPE); October 31, 2017. Brisbane, Australia.
Harris D, Midkiff K, Gilsenan A, Kellier-Steele N, McSorley D, Andrews EB. Study update for a postmarketing case series study of adult osteosarcoma and teriparatide in the US. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):314. Previously presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). doi: 10.1002/pds
Saltus CW, Harris DH, Calingaert B, Andrews EB, Zong J, Soriano-Gabarro M, Persson Brobert G, Kaye JA. Identification of second primary malignancies (SPM) in men with castration-resistant prostate cancer (CRPC) in SEER-Medicare data. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 29, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl):294. doi: 10.1002/pds
Harris D, Midkiff K, Gilsenan A, Andrews E. Twelve-year study update for a postmarketing case series study of adult osteosarcoma and teriparatide in the U.S. Poster presented at the North American Association of Central Cancer Registries (NAACCR) 2017 Annual Conference; June 21, 2017. Albuquerque, NM.
Kaye JA, Saltus CW, Calingaert B, Harris DH, Hunter S, Zong J, Brobert GP, Soriano-Gabarro M, Andrews EB. Incidence of Second Primary Malignancies (SPM) in men with Castration-Resistant Prostate Cancer (CRPC) in SEER-Medicare database. J Clin Oncol. 2017 May;2017(35):e13080.